Retina

Understanding the latest innovative technologies.

A research team for the $3.3 million study will assess the front and the back of the eye and different types of glucose dysfunction.

Some cases require unorthodox approaches.

It’s time to act with a few rational and relatively modest proposals.

Comanagement is a key component for treatment of disease.

The new smart glasses utilize artificial intelligence to visually assist those with age-related macular degeneration and other retinal disorders causing vision loss.

Case complexity underscores the importance of interdisciplinary communication.

The study helped identify predisposing factors for severe SANS in astronauts.

A new analysis by researchers at the National Institutes of Health shows the benefit of taking AREDS2 formula in late AMD.

The 2-year Phase III data demonstrates Susvimo’s potential as an alternative to eye injections to treat diabetic macular edema and diabetic retinopathy.

Study investigators conducted a case-control study to investigate the corneal topography parameters and biomechanics in patients with alopecia areata.

Pediatric TINU syndrome is rare, but responds well to treatment.

According to Genentech, faricimab-svoa is the first and only syringe that is prefilled with an FDA-approved bispecific antibody to treat wet AMD, DME and RVO.

The company also submitted a marketing authorization application with the European Medicines Agency.

Respecting the clinical importance of the pachychoroid spectrum is vital when analyzing OCT scans.

Neurotech's ocular implant NT-501 utilizes encapsulated cell therapy to slow the progression of macular telangiectasia type 2 (MacTel). The implant was given a PDUFA goal date of December 17, 2024.

Pathogenesis and detection of diabetic retinopathy.

The study evaluates the efficacy, safety, and tolerability of 2 dose levels of AGTC-501 for the treatment of X-linked retinitis pigmentosa.

Positive data from the GALE long-term extension study showed patients developed fewer new scotomatous points with 36 months of both continuous monthly and every-other-month treatment.

The French study found that a complete capsular removal seemed to be the safer option for pediatric patients with Marfan syndrome in terms of risk of retinal detachment.

The biotechnology company is developing the first protein-based artificial retina for patients with retinitis pigmentosa and age-related macular degeneration.

DF-003 is a first-in-class, oral, potent, highly selective alpha-kinase 1 (ALPK1), an inhibitor believed to be responsible for causing ROSAH syndrome.

The trial evaluates OCU410ST, a modifier gene therapy candidate utilizing an AAV delivery platform for the retinal delivery of the RORA gene. The gene therapy is being designed as a one-time treatment for life.

The AI-powered eye diagnostic innovator and medical devices and software solutions company have announced a collaboration to promote an AI diagnostic tool that assesses risk to brain health via retinal imaging.

The Diffusion Optics Technology, or DOT 0.2, works by utilizing thousands of light scattering elements to mimic natural contrast on the retina, which can slow myopia progression in child, according to the company.

The technology works by concentrating a specific band of light, typically 650 nm, into a laser beam to irradiate the retina.

The diagnostic screening technology is able to diagnose diabetic retinopathy by using 1 image taken of each eye with over 99% imageability.

The non-randomized, open label, safety and efficacy study will inject a sustained release implant in 5 participants.

Early detection of incipient geographic atrophy is critical to identify patients at greatest risk of progression and who may benefit most from newly approved complement inhibition therapies.

The AI-powered model works to detect early signs of glaucoma and makes iHealthScreen the first company to receive 2 US patents for AMD and glaucoma screening devices.